Treatment of noninfectious uveitis

被引：0
作者：
Ferreira, Lisia Barros [1 ]
Farrall, Alexandra L. [1 ]
Furtado, Joao M. [2 ]
Smith, Justine R. [1 ]
机构：
[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Div Ophthalmol, Ribeirao Preto, SP, Brazil
来源：
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA | 2021年 / 84卷 / 06期
关键词：
Uveitis; Noninfectious uveitis; Immunomodulatory therapy; Biologics; Inflammation; JUVENILE IDIOPATHIC ARTHRITIS; INTRAVENOUS IMMUNOGLOBULIN THERAPY; INFLAMMATORY EYE DISEASE; CYSTOID MACULAR EDEMA; INTRAVITREAL TRIAMCINOLONE; RITUXIMAB THERAPY; CLINICAL-TRIAL; INTERMEDIATE UVEITIS; CERTOLIZUMAB PEGOL; EFFICACY;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Uveitis is a broad term that refers to a large group of eye disorders categorized by intraocular inflammation, a leading cause of visual impairment. Historically, treatment of noninfectious uveitis has depended on corticosteroid drugs. Owing to the myriad of side effects caused by corticosteroids, immunomodulatory therapy has become the preferred treatment for chronic noninfectious intraocular inflammation. Recently, biological response modifiers have established a new era in uveitis therapy, with the range of targets continuing to expand. In this review, we aimed to convey up-to-date information on the treatment of noninfectious uveitis to thegeneral ophthalmologist.
引用
收藏
页码：610 / 621
页数：12
相关论文
共 50 条
  • [1] Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis
    Coureta, C.
    Ducloyer, J-B
    Touhanni, S.
    Angioi-Duprez, K.
    Rougier, M-B
    Labalettee, P.
    Titah, C.
    Cochereau, I
    Kodjikian, L.
    Mura, F.
    Chiquet, C.
    Weber, M.
    Bodaghi, B.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2020, 43 (04): : 341 - 361
  • [2] Adalimumab for the treatment of refractory noninfectious paediatric uveitis
    Munoz-Gallego, Alicia
    Barral, Estefania
    Enriquez, Eugenia
    Tejada, Pilar
    Barcelo, Ana
    de Inocencio, Jaime
    INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (03) : 719 - 725
  • [3] Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics
    Thomas, Akshay S.
    CURRENT OPINION IN OPHTHALMOLOGY, 2019, 30 (03) : 138 - 150
  • [4] Sirolimus for the treatment of noninfectious uveitis
    Pleyer, Uwe
    Thurau, Stephan R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (01) : 127 - 135
  • [5] Current Knowledge of Biologics in Treatment of Noninfectious Uveitis
    Gupta, Simple
    Shyamsundar, K.
    Agrawal, Mohini
    Vichare, Nitin
    Biswas, Jyotirmay
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 38 (03) : 203 - 222
  • [6] Adalimumab for the treatment of refractory noninfectious paediatric uveitis
    Alicia Muñoz-Gallego
    Estefanía Barral
    Eugenia Enríquez
    Pilar Tejada
    Ana Barceló
    Jaime de Inocencio
    International Ophthalmology, 2017, 37 : 719 - 725
  • [7] A systematic review of biologics for the treatment of noninfectious uveitis
    Takeuchi, Masaru
    IMMUNOTHERAPY, 2013, 5 (01) : 91 - 102
  • [8] Emerging drugs for the treatment of noninfectious uveitis
    Pleyer, Uwe
    Pohlmann, Dominika
    Kardes, Esra
    Poddubnyy, Denis
    Rademacher, Judith
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (03) : 173 - 190
  • [9] Novel therapies in the treatment of noninfectious uveitis
    Sandhu, Harpal Singh
    Kaplan, Henry J.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2018, 13 (03) : 139 - 147
  • [10] Single Dexamethasone Intravitreal Implant in the Treatment of Noninfectious Uveitis
    Frere, Ariane
    Caspers, Laure
    Makhoul, Dorine
    Judice, Lia
    Postelmans, Laurence
    Janssens, Xavier
    Lefebvre, Pierre
    Melot, Christian
    Willermain, Francois
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2017, 33 (04) : 290 - 297
12345